| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2134365 | Experimental Hematology | 2011 | 17 Pages |
Abstract
These data demonstrate that the Flt3-ITD confers sensitivity to Ara-C, but resistance to doxorubicin in a manner that depends on p53. Thus, patients with Flt3-ITD positive AML may not benefit from treatment with an anthracycline.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Timothy S. Pardee, Johannes Zuber, Scott W. Lowe,